Cell MedX Corp is a clinical-stage biopharmaceutical company focused on the development of next-generation prophylactic and therapeutic vaccines and immunotherapies targeting cancer and infectious diseases. Established as a spin-off in the mid-2000s and headquartered in Boca Raton, Florida, the company has built a pipeline of proprietary poxvirus-based vaccine platforms designed to elicit robust cellular and humoral immune responses. Key initiatives include novel approaches to treat solid tumors such as prostate and brain cancers, as well as rapid-development capabilities for emerging viral pathogens.
At the core of Cell MedX’s technology is its modified vaccinia Ankara (MVA) backbone, which serves as a delivery vehicle for tumor-associated or viral antigens. This platform is engineered to enhance antigen presentation and stimulate T-cell activation, with preclinical studies showing promising immunogenicity and safety profiles. Alongside its cancer programs, the company has leveraged the same platform to advance vaccine candidates for high-priority infectious agents, positioning it to respond swiftly to public health needs.
Cell MedX maintains collaborations with academic research centers and contract research organizations across North America and Europe. These partnerships support the company’s preclinical and clinical development activities, as well as the optimization of its manufacturing processes. By coordinating efforts across multiple geographies, Cell MedX aims to accelerate the timeline from discovery to clinic, while ensuring compliance with regulatory requirements in key markets.
Leadership at Cell MedX is led by Chief Executive Officer Dan Schechter, whose background spans over two decades in pharmaceutical development and translational medicine. The management team combines expertise in immunology, virology, and oncology, underpinned by a board of directors with experience in global biotech commercialization. Together, they are committed to advancing the company’s pipeline toward clinical milestones and ultimately delivering novel therapies for patients in need.
AI Generated. May Contain Errors.
Free CMXC Stock Alerts